Answers are grounded in this paper and cite their sources.
Objective: To evaluate the association between clinical outcomes and the volume of fluid boluses administered during the first 24 hours of a shock episode in extremely low gestational age newborns (ELGANs) requiring vasoactive support. Study Design: This retrospective cohort study included ELGANs (≤28 weeks) at a single Level IV NICU between 2013 and 2021 who received vasoactive medications for shock within the first seven days of life. The primary predictor was total fluid volume (cc/kg) administered in the first 24 hours of shock. Multivariable logistic regression adjusted for gestational age, birth weight, 5-minute Apgar score, systemic corticosteroid use, and highest vasoactive-inotropic score (VIS). Results: Of 97 infants, 26 (27%) died within 14 days of the shock episode. Non-survivors received a higher median bolus volume compared to survivors (40 cc/kg vs. 20 cc/kg, p<0.001). Greater bolus volume was independently associated with increased odds of 14-day mortality (aOR 1.026, 95% CI 1.004–1.048, p=0.019). Each additional 10 cc/kg was associated with an approximately 29% increase in mortality odds. No significant associations were found between bolus volume and severe intraventricular hemorrhage or bronchopulmonary dysplasia after adjustment. Conclusion: Greater cumulative fluid bolus volume was independently associated with higher 14-day mortality in ELGANs with shock requiring vasoactive support. Although residual confounding illness severity cannot be excluded, these findings support cautious, individualized use of volume expansion and highlight the need for prospective studies of hemodynamically targeted resuscitation in this population.
No takes yet. Share an insight, caveat, or question.
Eng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: